More MS news articles for August 2002

Strong Growth Prospects for U.S. Multiple Sclerosis Therapies Markets

Jul. 29, 2002
PR Newswire

SAN JOSE, Calif., Jul 29, 2002 /PRNewswire via COMTEX/ -- The market for multiple sclerosis (MS) therapies in the United States is poised for strong growth. Demand for MS drugs from both newly diagnosed as well as previously diagnosed but untreated patients contributes to increasing revenues.

New analysis from Frost & Sullivan ( ), U.S. Multiple Sclerosis Therapies Markets, reveals that this market generated revenues totaling $1.3 billion in 2001. Total market revenues are projected to reach $3.3 billion by 2008.

New patients are expected to drive the market.

"Future growth is largely dependent upon successful penetration of the newly diagnosed patient market, expansion into new categories such as primary progressive multiple sclerosis and development of oral drug formulations," says Frost & Sullivan Industry Manager Imran Khalifa.

The relapsing remitting multiple sclerosis (RRMS) category shows the highest demand for MS drugs. Research suggests that about 85 percent of MS patients begin with this type, prompting a number of manufacturers to develop therapies for its treatment.

"The market revenue potential of the RRMS group largely depends on the growth and penetration in the newly diagnosed patient segment," says Khalifa.

Several opportunities exist for companies to develop new drugs to meet the needs of the market. Typically, many RRMS patients progress to the secondary progressive (SPMS) phase of the disease. This pattern creates windows of opportunity for manufacturers to explore the relatively untapped potential of the SPMS category.

The market can expect to witness increased competition with the entry of new participants such as Serono, which is positioning its drug, Rebif, as a more viable alternative for treating RRMS. This has led manufacturers to work on developing interferon therapies and introducing innovative devices such as prefilled syringes.

"The successful development of an oral formulation has the potential to revolutionize the MS market," states Khalifa.

Frost & Sullivan is a global leader in strategic market consulting and training. This ongoing research is part of the Pharmaceuticals Monitor Service (9611) and the CNS Therapeutics Monitor Service (9629), that also includes market analyses on U.S. Anticonvulsant Medications (A062-52). Frost & Sullivan also offers custom consulting to a variety of national and international companies. Executive summaries and interviews are available to the press.

SOURCE Frost & Sullivan

Copyright © 1996-2002 PR Newswire Association LLC